SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity

Yale IMPACT Research Team

Research output: Contribution to journalArticlepeer-review

114 Scopus citations

Abstract

Background: Scaling SARS-CoV-2 testing to meet demands of safe reopenings continues to be plagued by assay costs and supply chain shortages. In response, we developed SalivaDirect, which received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Methods: We simplified our saliva-based diagnostic test by (1) not requiring collection tubes with preservatives, (2) replacing nucleic acid extraction with a simple enzymatic and heating step, and (3) testing specimens with a dualplex qRT-PCR assay. Moreover, we validated SalivaDirect with reagents and instruments from multiple vendors to minimize supply chain issues. Findings: From our hospital cohort, we show a high positive agreement (94%) between saliva tested with SalivaDirect and nasopharyngeal swabs tested with a commercial qRT-PCR kit. In partnership with the National Basketball Association (NBA) and National Basketball Players Association (NBPA), we tested 3,779 saliva specimens from healthy individuals and detected low rates of invalid (0.3%) and false-positive (<0.05%) results. Conclusions: We demonstrate that saliva is a valid alternative to swabs for SARS-CoV-2 screening and that SalivaDirect can make large-scale testing more accessible and affordable. Uniquely, we can designate other laboratories to use our sensitive, flexible, and simplified platform under our EUA (https://publichealth.yale.edu/salivadirect/). Funding: This study was funded by the NBA and NBPA (N.D.G.), the Huffman Family Donor Advised Fund (N.D.G.), a Fast Grant from Emergent Ventures at the Mercatus Center at George Mason University (N.D.G.), the Yale Institute for Global Health (N.D.G.), and the Beatrice Kleinberg Neuwirth Fund (A.I.K.). C.B.F.V. is supported by NWO Rubicon 019.181EN.004.

Original languageEnglish (US)
Pages (from-to)263-280.e6
JournalMed
Volume2
Issue number3
DOIs
StatePublished - Mar 12 2021
Externally publishedYes

Keywords

  • COVID-19
  • SARS-CoV-2
  • Translation to Patients
  • molecular testing
  • population screening
  • saliva

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity'. Together they form a unique fingerprint.

Cite this